Thymalin

Thymus peptide bioregulator

Thymalin is a peptide complex extracted from calf thymus — not a single molecule, and that distinction runs through everything on this page. It also has the strongest human trial in this entire class: a randomized, placebo-controlled study with a hard endpoint. That is rare enough here to be worth reading carefully, including its limits.

What Thymalin actually is — and why that changes the mechanism

Thymalin is not a molecule. It is a peptide complex extracted from calf thymus, and every sentence about its mechanism has to survive that fact first. There is no sequence to state, no mass to confirm, and no single structure whose behavior could be modeled.

What the originating group actually claims. Kuznik and colleagues state it plainly: “the molecular mechanism of the Thymalin immunoprotective action is due to the effects of the short peptides KE, EW, EDP in its composition.” That is a real, testable, falsifiable claim, and it is more specific than anything the extract's own marketing says. Two of those three peptides are sold separately in this same Vault — KE is Vilon, EW is Thymogen — which means the claim has an obvious experiment attached to it that nobody has run.

Why that claim is load- bearing and fragile at the same time. If Thymalin works through KE, EW and EDP, then the defined peptides should reproduce its effects, and the extract is a less precise way of buying them. If they do not, then whatever Thymalin does is coming from something in the complex nobody has identified — and in that case no synthetic peptide in this catalog substitutes for it. Those are opposite conclusions with opposite buying implications, and the literature does not yet distinguish them.

The mechanism claim for KE itself. The gene- regulation review credits Lys-Glu with regulating 36 genes and names it as the constituent of Thymalin showing optimal binding to a specific DNA sequence. So the extract's mechanism story ultimately rests on a dipeptide-DNA docking result — a computed energy score, not a measured affinity. Everything about the thymus complex is one inference removed from that.

What the primary literature on Thymalin actually says

Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients
Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N · Advances in Gerontology 2021;11(4):368–376

A prospective, randomized, single-blind, placebo-controlled trial in severe COVID-19 in older patients at one hospital in Chita, Russia. Thymalin plus standard therapy, n=36, against saline placebo plus standard therapy, n=44 — a ten-day intramuscular course, with blood measured at baseline and again on day 14. The immune arithmetic is specific: blood lymphocytes +92% where control did not move; T-lymphocytes +2.2-fold, B-lymphocytes +2-fold, NK cells +2.4-fold, CD4+ +2.2-fold, CD8+ +2.2-fold, CD3+HLA-DR+ +3.4-fold, all against no significant control change. C-reactive protein fell 3.3-fold against 2.2-fold in control; IL-6 fell 6.5-fold, D-dimer 1.5-fold, fibrinogen 30% and LDH 1.9-fold, none of which moved significantly in control. Hospital mortality was reported halved; the absolute rates are not in the abstract.

Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363

The 266-subject elderly series over 6–8 years, and the origin of nearly every longevity claim made for this class. Acute respiratory disease incidence fell 2.0–2.4-fold. Mortality is reported 2.0–2.1-fold lower with Thymalin, 1.6–1.8-fold lower with Epithalamin, 2.5-fold lower combined, and 4.1-fold lower with annual combined treatment for six years.

Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147

The mechanism claim that ties the extract to the defined peptides. The wording that matters is in the COVID paper above, not this one — Kuznik et al. state that “the molecular mechanism of the Thymalin immunoprotective action is due to the effects of the short peptides KE, EW, EDP in its composition.” This review is what supplies the gene-level detail behind that sentence: KE is credited with regulating 36 genes, and is named here as the constituent of Thymalin that shows optimal binding to a specific DNA sequence. Two of those three peptides are sold separately, as Vilon and Thymogen.

Why the Thymalin evidence is weak — and what it still showed

Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.

Specific to Thymalin. Take the two papers in order, because they are not the same kind of evidence. The COVID trial is genuinely a trial: randomized, placebo-controlled, single-blind, prespecified immune endpoints, one hard outcome. Its limits are that it is single-center, run by the group that developed the drug, single-blind rather than double, and n=80 total — small enough that a mortality halving is compatible with a handful of events either way, which is exactly why the absolute rates matter and are not given. The 6–8 year series is a different animal: no randomization described, no blinding, no pre-registration, endpoints selected after the fact, and an effect size — 4.1-fold lower all-cause mortality — larger than any intervention in medicine. Smoking cessation does not do that. An effect that big, unreplicated outside the originating group for two decades, is a reason to look harder, not a reason to believe.

What the data does support — and this is the strongest human evidence anywhere in the class. Kuznik et al. 2021 is a prospective, randomized, single-blind, placebo-controlled trial in severe COVID-19 in older patients at one hospital in Chita, Russia: Thymalin plus standard therapy, n=36, against saline placebo plus standard therapy, n=44, a ten-day intramuscular course with bloods at baseline and day 14. The immune arithmetic is specific and it is prespecified: blood lymphocytes +92% where control did not move; T-lymphocytes 2.2-fold, B-lymphocytes 2-fold, NK cells 2.4-fold, CD4+ 2.2-fold, CD8+ 2.2-fold, CD3+HLA-DR+ 3.4-fold. C-reactive protein fell 3.3-fold against 2.2-fold in control; IL-6 fell 6.5-fold, D-dimer 1.5-fold, lactate dehydrogenase 1.9-fold and fibrinogen 30%, none of which moved significantly in control. Hospital mortality was reported halved.

Now the limits, honestly. Single-center. Run by the group that developed the drug. Single-blind, not double. And n=80 total, which is small enough that a halving of mortality is compatible with a handful of events either way — the absolute rates are not in the abstract, and that omission is exactly where a reader should push back. The 266-subject, 6–8-year elderly series is a different and much weaker animal: no randomization described, no blinding, endpoints selected after the fact, and a headline effect — 4.1-fold lower all-cause mortality with annual combined courses — larger than any intervention in medicine has ever produced. An effect size that big in an uncontrolled series is evidence about the design, not about the drug.

The specific epistemic position here is unusual for this catalog: Thymalin has a positive randomized trial that nobody outside its own institute has attempted to replicate. That is not the same as no evidence, and it is not the same as replicated evidence. It is a single small positive result sitting alone, which is the state at which most promising drugs are also indistinguishable from the ones that later fail.

What is actually measured, and what is not. Measured, in a randomized controlled trial: n = 36 against n = 44 over a ten-day course, with lymphocytes up 92%, CD4+ and CD8+ each 2.2-fold, NK cells 2.4-fold, IL-6 down 6.5-fold and fibrinogen down 30%. Not measured: the absolute mortality rates behind the reported halving; the composition of the extract by mass spectrometry; the plasma half-life or clearance of any component; and whether any other manufacturer's thymus preparation behaves the same.

Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.

Thymalin pharmacokinetics — how much of it actually gets in

Why there is no half-life, and why that is the correct answer. A half-life describes the clearance of one compound. A mixture of peptides of different lengths and charges has as many clearance curves as it has components, so “~30 min” as printed in the quick facts above is a figure for something, but nobody can say for what. It has no traceable human study behind it.

What can still be reasoned. The short components are exposed to the same serum aminopeptidases as any other peptide and clear in minutes. That does not undermine the claim — the proposed mechanism is a transcriptional signal, and a signal that changes gene expression does not need to still be in the blood when the effect appears. It does mean measuring the drug in serum would tell you nothing, which is why the trial below measured lymphocyte subsets instead of drug levels. That was the right call.

Route, and the number that bounds it. The trial that gives this compound its credibility used intramuscular injection — 100% bioavailable, no gut wall, no hepatic first-pass. Thymalin is sold here in injectable form only, and that is consistent rather than accidental: a protein hydrolysate is not a PEPT1 substrate, because PEPT1 carries di- and tripeptides and not peptide mixtures of unknown chain length. Anyone selling an oral thymus complex on the strength of this trial is citing evidence generated by a route their product does not use.

The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.

What would have to be true for Thymalin to work

What would have to be true. The extract would have to contain short peptides at a concentration that survives injection and reaches lymphoid tissue; those peptides would have to enter lymphocytes and their nuclei; and the resulting transcriptional change would have to be large enough to shift cell counts you can see on a differential. Unlike most of this catalog, the last step here has been observed in a randomized trial — which is why the useful predictions for Thymalin are about replication rather than about plausibility.

Every one of these is a standard, orderable test. That is the point.

1. Prediction 1 — Complete Blood Count (CBC) with Differential. absolute lymphocyte count should rise measurably in someone starting from a low count, by the end of a 10-day course. This is the trial's own headline effect and it costs almost nothing to check. If lymphocytes do not move in a lymphopenic person, the immune claim has failed its easiest test.
2. Prediction 2 — CD4/CD8 ratio. the subsets should move together rather than one alone, by the end of a course. The trial reported CD4+ and CD8+ each rising 2.2-fold — the same factor, which is why the ratio barely shifted. That symmetry is the specific, checkable signature: a compound that moved one subset without the other would not be reproducing what was published, and a ratio that swings hard is evidence of something else going on.
3. Prediction 3 — hs-CRP (High-Sensitivity C-Reactive Protein). should fall further and faster than it would on its own, within 14 days, on the trial's timeline. CRP fell in both arms of the trial — the claim is a bigger fall, not a fall. A single-arm before/after will therefore prove nothing here, which is worth knowing before you spend the money.
4. Prediction 4 — d-dimer. should fall, alongside fibrinogen, within 14 days. The coagulation arm of the result is the least expected part and the easiest to falsify. If D-dimer and fibrinogen do not track together, the reported effect is more likely to have been the underlying illness resolving.

Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Thymalin did to it — and that difference is the entire point of testing.

Thymalin versus the alternatives

Thymalin versus Thymogen. Thymogen is Glu-Trp — one of the three peptides Kuznik names as the reason Thymalin works. So the extract and the defined dipeptide are not competitors so much as a hypothesis and its test. If the dipeptide reproduces the extract's lymphocyte effects, the extract is redundant and harder to verify. If it does not, the KE/EW/EDP explanation is wrong. Nobody has run that comparison in humans, and it would be one of the cheapest informative studies in this entire field.

And against the credible conventional alternative — thymosin alpha-1. This is the comparison the bioregulator market avoids, and it does not go well. Thymosin alpha-1 is a defined 28-residue peptide with a known sequence, registered clinical use in several countries, and a multi-country trial record in hepatitis B, sepsis and as a vaccine adjuvant — including trials run by people with no commercial stake in it. Thymalin has one randomized trial from its own institute. If you are choosing on evidence, that is not a close call, and the honest reason to be reading this page at all is that you already know it.

What you are actually buying when you buy Thymalin

Thymalin is an extract, not a molecule, and this is the single most important paragraph on the page for anyone about to buy one. A certificate of analysis on a tissue extract can establish sterility, endotoxin load, total protein and the absence of named contaminants. It cannot establish identity, because there is no structure to identify — the product is defined by its manufacturing process, not by a formula. Two vials with clean certificates can legitimately hold different mixtures. That is not an allegation about any vendor; it is what an extract is, and no laboratory test resolves it.

It also means the trial above is evidence about one manufacturer's preparation, made to one process. There is no assay that would tell you whether the vial in front of you matches it. That is a much bigger caveat than the usual purity discussion, and it applies to every extract in this catalog.

This is where extracts and peptides part company. A certificate of analysis on a tissue extract can establish sterility, endotoxin, total protein and the absence of named contaminants. It cannot establish identity, because there is no single molecule to identify — the product is defined by its process, not its structure. Two vials with clean CoAs can contain different mixtures. That is not a smear on any vendor; it is what an extract is.

Where to get Thymalin

The evidence for Thymalin

Graded by what exists behind each claim.

✅ Clinically validated

• The strongest clinical record in the whole bioregulator series, and it is still Russian. Registered in Russia and used clinically since the 1980s for immune deficiency and as an adjunct in infection and oncology.
• Khavinson's group published a 6–12 year follow-up in elderly patients given Thymalin (alone or with Epithalamin) reporting reduced all-cause mortality against controls. That is an unusually ambitious endpoint and an unusually long follow-up — and it has never been independently replicated, which is why it sits here rather than in a guideline.

📊 Correlative data

• Decades of Russian clinical use in immunosuppressed patients, with a long practical safety record in that setting. Used in courses of five to ten injections rather than continuously.
• Reported use outside Russia is mostly by older users targeting immune decline, which is the population the mortality data came from.

🧪 Theoretical / extrapolated

• A polypeptide fraction extracted from calf thymus, proposed to restore T-cell maturation — the thymus involutes with age, and thymic decline is a well-established driver of immunosenescence, so the target itself is not controversial.
• Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
• One genuine caution the mechanism predicts: something that up-regulates T-cell activity is the wrong direction in autoimmune disease or on immunosuppressant therapy after transplant.

What that tier rests on here. Unusually for this class, part of the tier above rests on a randomized, placebo-controlled human trial with prespecified immune endpoints. It is single-center, single-blind and small (n=80 total), and nobody outside the originating institute has replicated it.

The Khavinson series, in full →

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

Cell, rodent, human — and where it stops

The most important thing published about Thymalin is that it may not need to be Thymalin. Linkova 2023 states plainly that KE and EW dipeptides are the active substances of the drug. Both are sold on this site under their own names — KE as Vilon, EW as Thymogen. If the paper is right, the thymus extract is a delivery vehicle for two molecules you can buy defined, weighed and mass-verified. The paper comes from the manufacturer's own research group, which is what makes it worth reading twice.

In silico, then in cells, and the n is small enough to print. The same work docked both dipeptides against double-stranded DNA and reported a preferred site for each: GGAG for EW in classical B-form DNA, GCGC for KE in the curved nucleosomal form. Bioinformatics assigned candidate targets — AKT1 and AKT2 for both, ACE2 and CYSLTR1 specific to EW, CHUK specific to KE. Then human peripheral blood mononuclear cells were stimulated with lipopolysaccharide and assayed by ELISA. IL-1β, IL-6 and TNF-α fell by 1.4 to 6.0 times. Blood came from four donors. That is the sample size of the cell experiment behind the mechanism.

In people. Khavinson 2021 adds Thymalin to standard COVID-19 therapy and reports faster falls in IL-6, C-reactive protein and D-dimer than standard treatment alone, with the group framing the mechanism as an effect on hematopoietic stem cell differentiation; Kuznik 2021 is the companion report. Human dosing goes back to Degtiarev 1988, an influenza-vaccine response study from 1988.

Where it stops, and the one crack of daylight. None of the clinical work was blinded or pre-registered, and all of it is one school. The exception is Boiko 2024, a 2024 rat study from a Ukrainian group publishing in a Polish journal that used Thymalin around a jaw bone defect and counted lymphocyte and macrophage populations. It is a long way from a COVID ward — but it is somebody else's hands on the same vial.

What nobody has tested yet

The three-arm trial the manufacturer's own paper implies. Thymalin against KE against EW, in the same inflammation model, at matched molar exposure. If Linkova 2023 is correct, the extract should do nothing the two dipeptides cannot do between them. If it beats them, the extract contains something nobody has named yet, which would be a genuine discovery. Nobody has run it, and it is cheaper than most cell papers already published in this field.

A CD4/CD8 ratio before and after a course. This is a thymic product; lymphocyte subsets are the thymus's own read-out, they are available from any hospital laboratory, and the class has been sold for immune restoration for four decades without a published before-and-after pair in a healthy adult.

Extrapolation, labeled as such. EW is reported in the same paper to interact with ACE2. If that holds in a living person, then the interesting prediction is not immune at all — it is vascular, and it would show up as a change in blood pressure or in endothelial function long before it showed up in a cytokine panel. No study of Thymalin has ever recorded a blood pressure. That is a free measurement, taken at every clinic visit, that would test a mechanism the group itself proposed.

Sources read for this page

• Linkova N. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences 2023 · PMID 37686182
• Khavinson VK. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Reviews and Reports 2021 · PMID 33575961
• Degtiarev AA. Use of thymalin in stimulating an immune response in subjects inoculated with influenza vaccine. Voenno-Meditsinskii Zhurnal 1988 [Russian] · PMID 3206835
• Boiko AA. Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues. Polski Merkuriusz Lekarski 2024 · PMID 38642352
• Khavinson VKh, Morozov VG. Geroprotective effect of thymalin and epithalamin. Advances in Gerontology 2002 [Russian] · PMID 12577695
• Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
• Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology 2021;11(4):368–376

Thymalin — safety, predicted from mechanism

Thymalin — safety specifics for this compound

Thymalin — interference & stacking

Bloodwork to run alongside Thymalin

Baseline first, then again at 8–12 weeks.

The Frequent Illness & Immune Resilience panel covers these in one order — 8 markers, $97.65 with the discount applied.

Check results you already have → · All 103 markers A–Z

Thymalin — frequently asked questions

References & further reading

1. Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N — Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients · Advances in Gerontology 2021;11(4):368–376
2. Khavinson VKh, Morozov VG — Peptides of pineal gland and thymus prolong human life · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
3. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147

Thymalin inside a finished plan

One arm of 2 Protocol Blueprints, free to read in full.

What Thymalin is used for

Thymalin appears under 2 goals in the goal router.

Related Longevity & Bioregulators compounds

← Explore the full Protocol Vault

↑ Back to on this page